key: cord-0883634-8uy6lhjz
authors: Huang, X.; Tang, G.; Ismail, N.; Wang, X.
title: Developing RT-LAMP Assays for Detection of SARS-CoV-2 in Saliva
date: 2021-04-26
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2021.04.25.21256085
sha: 811ce009236a37472ba1ccb011c1cae4b928b652
doc_id: 883634
cord_uid: 8uy6lhjz

The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has killed millions of people worldwide. The current crisis has created an unprecedented demand for rapid test of SARS-CoV-2 infection. Reverse transcription loop-mediated isothermal amplification (RT-LAMP) is a fast and convenient method to amplify and identify the transcripts of a targeted pathogen. However, the sensitivity and specificity of RT-LAMP were generally regarded as inferior when compared with the gold standard RT-qPCR. To address this issue, we combined bioinformatic and experimental analyses to improve the assay performance for COVID-19 diagnosis. First, we developed an improved algorithm to design LAMP primers targeting the nucleocapsid (N), membrane (M), and spike (S) genes of SARS-CoV-2. Next, we rigorously validated these new assays for their efficacy and specificity. Further, we demonstrated that multiplexed RT-LAMP assays could directly detect as low as a few copies of SARS-CoV-2 RNA in saliva, without the need of RNA isolation. Importantly, further testing using saliva samples from COVID-19 patients indicated that the new RT-LAMP assays were in total agreement in sensitivity and specificity with standard RT-qPCR. In summary, our new LAMP primer design algorithm along with the validated assays provide a fast and reliable method for the diagnosis of COVID-19 cases.

The pandemic of COVID-19 has killed over 2.7 million people worldwide, including over 545,070 in the USA as of March 25, 2021 . More than 124 million people have been infected worldwide.

Each day, hundreds of thousands are added to the numbers (while this manuscript was being prepared). Rapid testing to identify the SARS-CoV-2 positive population followed by quarantine is important to curb the pandemic. Thus, the current crisis has created an unprecedented demand for rapid tests with high sensitivity and specificity for point-of-care diagnosis. Vaccine distribution has curbed the pandemic significantly, although it is also expected that the virus will be present in communities in the long term 1 .

To detect SARS-CoV-2, many research groups have developed new diagnostic assays based on various technology platforms. Among them, nucleic acid detection by reverse transcription quantitative PCR (RT-qPCR) is considered the gold standard for virus diagnosis. In addition, there are other alternative nucleic acid detection methods developed in recent years, providing fast diagnostic results 2 . However, these newly emerged methods generally have inferior diagnostic performance compared with RT-qPCR 3 . Among these methods, loop-mediated isothermal amplification (LAMP) was developed by Notomi T et al. in 2000 4 . Since then, LAMP has been widely adopted for the detection of many pathogens, such as malaria 5 , salmonella 6 , influenza virus 7 , dengue virus 8 , Chikungunya virus 9 , and Zika virus 10 . Although multiple groups have attempted to apply the LAMP technique to SARS-CoV-2 detection [11] [12] [13] , there are still major unresolved technical challenges preventing its application in clinical settings.

The advantage of LAMP assays mainly lies in their fast turnaround time and simplicity in assay setup. Specifically, LAMP does not require high-end instruments, making it widely accessible worldwide including developing countries. Moreover, LAMP works well even for a variety of unpurified samples, which is important for convenient and fast assay setup. Another major advantage is that LAMP readout can be colorimetric or turbidity changes, easily visualized and recorded by a phone camera. In addition, being performed under lower temperatures than PCR, LAMP can be easily combined with the RT reaction (RT-LAMP), directly detecting target RNA without a separate RT step. In this way, the total reaction time can be greatly shortened.

Therefore, LAMP is a powerful tool for point-of-care diagnosis with wide applications 2 . Despite these advantages, current LAMP assays are regarded as inferior to RT-qPCR in detection sensitivity and specificity 11, 14 .

Compared with PCR, LAMP is still an emerging technology with major unresolved issues. It is a major challenge to design robust LAMP assays for pathogen detection. A typical LAMP assay requires six primers targeting eight regions of the target sequence ( Fig. 1 ). At present, few tools are available publicly for LAMP primer design, and available tools did not sufficiently consider the complexity of LAMP reactions. For example, one major issue is related to high level of unintended primer cross-reactivity, given that a set of six primers are included in a single LAMP reaction. This frequently leads to false-positive results as reported by many investigators 11, [15] [16] [17] [18] .

In this study, we developed an improved bioinformatics algorithm to design LAMP primer sets targeting the nucleocapsid (N), membrane (M), and spike (S) genes of SARS-CoV-2. The performance of these primer sets was rigorously validated experimentally. A combination of the best primer sets could reliably detect as low as a few copies of SARS-CoV-2 RNA in unpurified specimens (i.e., saliva) without the need of RNA isolation. This represents significant improvement over other reported LAMP assays [11] [12] [13] . Finally, further testing using simulated saliva samples as well as patient saliva samples indicated that our new assays were as effective as standard RT-qPCR in SARS-CoV-2 detection. Importantly, our assays have unique advantages over RT-qPCR due to their fast and direct detection of viral RNA in saliva with colorimetric readout, making it ideal for inexpensive point-of-care diagnosis. Our new LAMP All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2021. ;  https://doi.org/10.1101/2021.04.25.21256085 doi: medRxiv preprint design method as well as experimentally validated assays provide a valuable resource to fight the pandemic of COVID-19.

One major goal of our study was to improve the efficacy of LAMP assays for SARS-CoV-2 detection. During the LAMP reaction, the amplification stage is initiated with the formation of a dumbbell structure, in which F1/F1c (or B1/B1c) and F2 (or B2) form the stem and loop, respectively ( Fig. 1 ). As the first step, two long inner primers, FIP (F1c+F2) and BIP (B1c+B2) are annealed to the target to initiate the LAMP reaction. In general, long oligo primers have relatively poor annealing efficiency due to the potential formation of secondary structures. The poor annealing efficiency of long oligo primers has been extensively documented in numerous PCR studies 19 . Thus, we reasoned that the efficacy of LAMP assays could be improved by shortening the FIP and BIP primers. To this end, we determined the optimal length of the stem region (F1c or B1c) within the primers. As shown in Table 1 , we first designed N1(-3), and N2(-5) assays, which had shortened stems (as compared to standard design) to target the N gene of SARS-CoV-2. The shortening of the stems resulted in significantly improved TT values in comparison to that of original N1 and N2 assays ( Fig. 2A) . Thus, it was clear that standard LAMP design guidelines for the dumbbell structure, as recommended by previous studies 4, 20 , should be further optimized.

To comprehensively determine the optimal length of the stem region, we further designed twenty primer sets with variable F1c and B1c lengths (derived from the N1 to N6 assays). The testing results and the sequences of these primer sets are summarized in Table 1 and   Supplementary Table S1 , respectively. Both the length and melting temperature (Tm) of the stem region were important determinants of assay efficiency. While stem shortening helped All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. improve TT values as compared to the standard design, excessive further shortening of the stem region was detrimental as a result of significantly lowered Tm value. Based on these 24 LAMP primer sets, observed optimal stem length was in the range of 12-17 bp with Tm >45°C.

Besides amplification efficiency (as represented by TT), another major consideration of LAMP performance is the specificity of the assays. False-positive products are commonly observed in LAMP reactions even in the absence of nucleic acid targets, as reported by numerous studies 11, [15] [16] [17] [18] . For example, multiple LAMP assays derived from the N6 assay (Table 1) showed various levels of false-positive readout in the absence of the target template (Fig. 2B) . Thus, it is crucial to design primer sets with low cross-reactivity to avoid false-positive amplification. To this end, we categorized potential false-positive (FP) reactions into four levels (FP scores 1-4) during primer screening with representative examples listed in Fig. 2B: 1 ) FP score of 1, no or minimal fluorescence signals at the endpoint, as represented by N6(-4) and N6(-6) assays; 2) FP score of 2, low but detectable fluorescence signal at the endpoint, as represented by N6(-2); 3) FP score of 3, high fluorescence signals detected during the late stage of the reaction (45-90 min), as represented by N6(-2/-) and N6(-/-2); 4) FP score of 4, false amplification observed during the early stage of the reaction (<45 min), as represented by N6. By employing this color-coded scoring scheme, we were able to concurrently evaluate both the efficiency and specificity of the LAMP assays (Fig. 2C ).

LAMP assays with various FP scores had distinct colorimetric readouts and electrophoresis patterns in the absence of target DNA (Fig. 2D&E) . Specifically, for assays with an FP score of 1 or 2, no colorimetric change was observed (Fig. 2D , pink wells in the right section for N6(-2), N6(-4), and N6(-6) assays). In addition, no amplification product was observed by gel electrophoresis (Fig. 2E, lanes 10-12) . For assays with a score of 3 or 4, non-specific products All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Fig. 2D , yellow or orange wells in the right section for N6, N6 (-2/-), and N6(-/-2)] and gel electrophoresis (Fig. 2E, lanes 7-9) . Interestingly, the size distribution of non-specific products was distinctively different from that of on-target products ( Fig. 2E lanes 1-6 vs. 7-9 ). To maximize assay specificity, in our study, only primer sets with an FP score of 1 were further evaluated with the goal of developing robust assays for SARS-CoV-2 diagnosis.

To understand the mechanism underlying the false-positive reactions, we further analyzed nonspecific products from the N6 assay. The N6 primer set was prone to false-positive reaction, having an FP score of 4. Further analysis of the non-specific products by electrophoresis showed that false-positive reaction happened in an FIP/BIP dependent manner ( Supplementary   Fig. S1A ). The false-positive reactions could occur even in the absence of FL, BL, F3, and B3 primers (lanes 5-8, FP 3-4), but not in the absence of FIP/BIP primers (lanes 9-12). Thus, it was clear that the FIP/BIP primers in the N6 assay were responsible for the false-positive products.

We further characterized the false-positive products by high-throughput sequencing. To this end, PCR primers with F2 or B2 sequence at the 3'-end were used to amplify non-specific LAMP products from the N6 assay (Supplementary Table S2 ). Sequencing showed that both FIP and BIP primers were incorporated into the non-specific products, with new linker sequences (1-5 bp) inserted between FIP and BIP ( Supplementary Fig. S1B) . These results support a model that tandem linkage of FIP and BIP is responsible for the false-positive LAMP reactions ( Supplementary Fig. S1C ).

Based on the above experimental data for assay optimization, we developed an improved bioinformatics algorithm for designing LAMP primers for SARS-CoV-2 diagnosis. This algorithm incorporated many design features that were proven to be important for DNA amplification in our All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. [21] [22] [23] . In addition, the new algorithm also included novel features that are unique for LAMP assays. As summarized in Fig. 3 , we first downloaded all 106,439 SARS-CoV-2 genome sequences submitted to the GISAID database (https://www.gisaid.org) as of September, 2020. These genome sequences were aligned to identify consensus viral genome sequence. In our assays, we excluded target regions that contain any variable nucleotide (<98% consensus).

Next, single primer candidates were selected from the target region, and a primer candidate would be discarded if any one of the following criteria was not met. The Tm value of the primer was in the range of 60-64°C, except for F1c/B1c candidates (Tm >45°C). All Tm values were calculated using the Nearest Neighbor method 24, 25 . To avoid potential primer cross-reactivity due to low sequence complexity, a stretch of continuous same nucleotides was not allowed (4 C's, 4 G's, 5 A's, or 5 T's). To further exclude sequences of low complexity, the DUST program 26 was employed, and any sequence identified by DUST was rejected. In addition, the GC content of the primer was in the range of 35-65% to ensure uniform priming. The 3'-end of the primer contributes most to non-specific primer extension, especially if the binding of these nucleotides is relatively stable 27 . Thus, the ∆G value of five residues at the 3'-end was calculated, and a threshold value of -8 kcal/mol was used for sequence rejection. The design algorithm further assessed potential secondary structures, which could hinder primer annealing to the template, leading to reduced amplification efficiency; primer secondary structures could also result in non-specific LAMP products by initiating unintended mispriming events. In our design, we implemented multiple secondary structure filters for primer screening as we described previously [21] [22] [23] . In addition, the Mfold program 28 was employed to exclude primer candidates with a low ∆G value of predicted secondary structure.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. After single primer candidates were selected, the design algorithm then chose compatible primer pairs that show no cross-reactivity based on sequence match 21 . In particular, more stringent selection filters were applied to the end residues of paired primers to prevent the formation of primer heterodimers. Based on compatible primer pairs, the F and B primer subsets were selected, which were further assembled into a six-primer set for the LAMP assay. F1c and F2 were combined into the forward annealing primer (FIP); similarly, B1c and B2 were combined into the reverse annealing primer (BIP). Unintended primer cross-reactivity is a major challenge for DNA amplification, especially when multiple primers are included in the same reaction. To alleviate this concern, our algorithm includes filters to evaluate potential primer dimer formation or other mispriming events from all possible primer pairs among the six primers in the assay. Details of these cross-reaction filters were described previously [21] [22] [23] . Moreover, restraints were placed on the relative positions of each primer in the assay for efficient LAMP amplification ( Supplementary Fig. S2 ).

The algorithm described above was used to design LAMP primers for SARS-CoV-2 diagnosis.

As summarized in Fig. 4 and Supplementary Table S1, we tested the performance of 22 newly designed primer sets (N7-N28), as evaluated by both the TT value and FP score, to target the N gene sequence in a DNA plasmid. Most of these assays (n=19) had low FP scores (<=2), indicating high specificity of the LAMP reaction. Moreover, the majority of the assays (n=14) were able to detect the target with high efficiency, as demonstrated by low TT values (<30 min).

In particular, N7, N25, and N27 assays had the best overall performance, with both TT value less than 20 min and FP score of 1. Thus, these three assays were further evaluated for their diagnostic potential using the SARS-CoV-2 RNA genome as the target.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Besides primer sets for the N gene, we also designed and further tested six primer sets for the M gene and seven primer sets for the S gene, respectively, using SARS-CoV-2 RNA as the target (Fig. 5 and Supplementary Tables S3, S4 & S5) . All the M gene assays were highly efficient at detecting SARS-CoV-2 RNA (TT value close to or below 30 min). Among them, M5 and M6 assays had the best overall performance (TT value close to or below 15 min with FP score of 1). Thus, these two assays were selected for further evaluation. As for the S gene assays, they had similar efficiency as compared to the M gene assays, but with elevated levels of non-specific amplification. Among them, S1, S4, and S7 assays had no observed non-specific products, with an FP score of 1. In the same way, we also tested selected N gene assays by RT-LAMP for viral RNA detection. Altogether, we identified five primer sets, N2(-5), N7, N27, M5, and M6, which had the best overall performance for both amplification efficiency and specificity and M6 had a rate of 53% (average TT of 41 min). When only 1 cp/µL of RNA was added to the reaction (based on serial dilution), the positive rate of viral detection was much lower for all these assays, ranging from 0-20%.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2021. We next sought to determine whether RT-LAMP sensitivity could be further improved when assays were combined for simultaneous detection of multiple genes. Among the validated assays, N7/N27 and M5/M6 assays were designed to target the N gene and M gene, respectively. Thus, we established two multiplexed assays based on N7+M6 and N27+M5, respectively. Both assays had no detectable background (FP score of 1). Notably, as shown in Fig. 6B&C , the efficiency and sensitivity of the multiplexed assays (as evaluated by TT and detection rate) were significantly improved over any single assay alone. Specifically, N7/M6 assay could reliably detect 5 cp/µL of viral RNA in about 33 min (with a detection rate of 95% vs.

80% for N7 and 53% for M6, Fig. 6B ). Similarly, N27/M5 assay could detect 5 cp/µL of RNA in 30 min (detection rate of 100% vs. 55% for M5 and 53% for N27, Fig. 6C ). Most noticeably, with 1 cp/µL of RNA (based on serial dilution), both multiplexed assays had significantly improved detection rate compared with the single assays (40-55% detection rates for the multiplexed assays vs. 10-30% for the single assays).

For clinical diagnosis, the human samples (e.g., saliva) to be tested contain transcripts of both virus and human origin. To evaluate potential assay cross-reaction to human RNA, we spiked in various amounts of SARS-CoV-2 genomic RNA into total RNA (10 ng/µL) from HeLa cells or pretreated human saliva. Consistent with the data presented in Fig. 6B&C , the RT-LAMP results showed that multiplexed N7/M6 and N27/M5 assays were efficient and sensitive at detecting as few as 5 cp/µL of viral RNA (100% detection rate with TT <30 min, Fig. 7A&B ) mixed with HeLa RNA. When only 1 cp/µL of viral RNA was tested, the detection rates of the multiplexed assays ranged from 70%-80% with the TT around 30 min. For pretreated saliva samples spiked with SARS-CoV-2 RNA, both assays showed similar but slightly decreased performance in sensitivity and efficiency compared with HeLa RNA (Fig. 7A&B) . Importantly, the reactions produced negative results (i.e., 0% detection rate) when viral RNA was omitted, indicating no cross-reactivity of the assays to HeLa RNA or saliva RNA. As a positive control, we also All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table S7 ) 29 , and the result indicated high efficacy of detection (TT ~10 min for HeLa RNA and ~16min for saliva RNA, respectively). We further evaluated colorimetric changes of the reactions for detecting target transcripts ( Supplementary Fig. S3 ), which showed consistent results to the fluorescent readouts ( Supplementary Fig. S3A & B) .

With the limit of detection (LOD, defined as ≥95% detection rate) at 5 cp/µL of viral RNA (Tables 2), N7/M6 and N27/M5 assays were highly efficient and specific when SARS-CoV-2 RNA was diluted with water or HeLa RNA. However, the LODs were relatively low for SARS-CoV-2 detection in saliva samples mainly due to the limited amount (0.5 µL) of pretreated saliva being added to the RT-LAMP mixture (the LODs at 800 cp/µL and 200 cp/µL of viral RNA in undiluted saliva for N7/M6 and N27/M5, respectively; Tables 2). To further increase the sensitivity for saliva testing, we increased the RT-LAMP reaction volume from 10 µL to 20 µL, such that more saliva could be added to the reaction. In addition, the amount of pretreated saliva being added to the reaction was optimized to 3 µL, according to a recent publication 30 as well as our testing data. Moreover, we observed that HPLC purification of the FIP and BIP primers further boosted the efficiency of RT-LAMP (data not shown).

Under these optimized assay conditions for saliva analysis, we tested the performance of the N7/M6 and N27/M5 assays by directly adding heat-inactivated SARS-CoV-2 particles into saliva (i.e., "simulated" COVID-19 samples). Both assays had an LOD of 67 cp/µL of viral particles in simulated saliva samples. Below the LOD threshold, the N7/M6 assay had a positivity rate of 70% for 33 cp/µL, 40% for 16 cp/µL, and 30% for 8 cp/µL of SARS-CoV-2 in undiluted saliva samples, respectively. Similarly, the N27/M5 assay had a positivity rate of 80% for 33 cp/µL, 60% for 16 cp/µL, and 30% for 8 cp/µL of virus, respectively (Tables 2). Besides the improvement in LOD, All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2021. ; https://doi.org/10.1101/2021.04.25.21256085 doi: medRxiv preprint assay time was also shortened to 70 min since viral RNA was detected in all samples within this timeframe while all negative control samples (0 cp/µL) remained negative for viral detection (data not shown).

To evaluate the clinical utility of the RT-LAMP assays, we compared three alternative methods for SARS-CoV-2 diagnosis with saliva samples. 1) RT-LAMP directly using saliva; 2) RT-LAMP using RNA isolated from saliva; and 3) RT-qPCR using RNA isolated from saliva. Currently, RT-qPCR is the most widely used method in the clinic for SARS-CoV-2 diagnosis mainly due to its high detection sensitivity and specificity. We evaluated a commonly used RT-qPCR assay, E-Sarbeco, which is recommended for COVID-19 diagnosis by the WHO and CDC 31 . Our validation data indicated that the E-Sarbeco assay had an LOD of 0.5 cp/µL (i.e., 14 cp/reaction) of SARS-CoV-2 RNA, while producing no false positive signals from the negative control (Ct >40). This result is consistent with previously reported data on the E-Sarbeco assay and is also in the same LOD range with other RT-qPCR assays for COVID-19 diagnosis 3, 32, 33 .

The experimental design for assay comparison was summarized in Fig. 8A . Both N7/M6 and N27/M5 assays reliably detected SARS-CoV-2 at 78 cp/µL or higher in simulated saliva samples (4 out of 4 repeats), using either saliva or RNA isolated from the saliva (Fig. 8B) . With 5-39 cp/µL viral particles added to the saliva, both RT-LAMP assays consistently produced positive results (1-3 positive reactions out of four replicates) when tested directly on the saliva. In comparison, the sensitivity of the assays using isolated saliva RNA was significantly higher, as almost all reactions were positive at the same viral concentrations (Fig. 8B) . At 1 cp/µL level, N7/M6 and N27/M5 assays produced 0 and 1 positive reaction (out of four replicates), respectively. In contrast, the same two assays produced two and three positive reactions, All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. respectively, when tested on isolated saliva RNA. As reference control, we also performed RT-qPCR using the E-Sarbeco assay, and observed positive results across all viral concentrations, with Ct values in the range of 29.3 to 36.4 (Fig. 8B) .

We further validated the two RT-LAMP assays using twenty clinical saliva samples originally acquired for COVID-19 diagnosis. Similar to the testing procedure for simulated saliva samples, we evaluated the performance of the RT-LAMP assays using both saliva and RNA isolated from saliva. As reference control, the E-Sarbeco RT-qPCR assay was also included for testing of saliva RNA. Out of the twenty cases, nine were tested positive (Fig. 8C , patients #1, 4, 9, 10, 22, 23, 26, 27, and 31) , and ten were tested negative (Fig. 8D, Table S6 ).

RT-LAMP is an emerging technology for molecular diagnosis of human pathogens. Compared with RT-qPCR, the advantages of RT-LAMP assays are clear: 1) The reaction is fast; 2) the assay setup does not require any expensive instrument; and 3) the reaction is relatively insensitive to sample impurity, making it possible to directly test crude samples without RNA isolation. Thus, RT-LAMP with colorimetric readout is particularly attractive for point-of-care diagnosis of infectious pathogens. For example, multiple investigators have attempted to All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Despite its potential as a powerful diagnostic tool, RT-LAMP has not been widely adopted in the clinical setting (in comparison of RT-qPCR). One major challenge is the design of robust LAMP primers. A LAMP assay includes a set of six primers, targeting eight regions of the nucleic acid sequence for amplification; thus, the primer design is complicated. Existing assay design methods often produce ineffective primer sets due to poor amplification efficiency or nonspecific amplification. As a result, high-quality LAMP assays are commonly developed by trial and error based on experimental testing of many designed primer sets. Due to the major challenges in LAMP primer design, most LAMP studies for COVID-19 diagnosis adopted previously published primer sets that had suboptimal performance 11, 30 .

To address the aforementioned challenges, we developed an improved algorithm for LAMP primer design to target SARS-CoV-2. First, we optimized the length of F1c/B1c to significantly boost the amplification efficiency. F1c and B1c make up the loop stem of the dumbbell structure, which is formed at the beginning of the LAMP reaction and serves as template to initiate the amplification phase (Fig. 1) . Second, Next-generation sequencing demonstrated that falsepositive reactions mainly resulted from unintended interactions between FIP and BIP, two longest primers that are required at much higher concentrations than other primers in the reaction. Thus, more stringent specificity filters should be applied to the design of FIP/BIP primers. Taking account of these LAMP-specific parameters as well as other common primer design criteria from our previous studies 21-23 , we developed an improved bioinformatics algorithm for LAMP primer design. Our design method is highly effective at producing highquality LAMP assays, as evidenced by the validation data for the primer sets targeting the N and M genes of SARS-CoV-2. However, for the S gene, it is still a challenge to design efficient primer sets, likely due to the higher GC content (58% for S vs.43% for M and 47% for N).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Saliva testing is an attractive method for COVID-19 diagnosis. 1) It is a non-invasive method for sample collection; 2) saliva can be collected by a non-medical care worker, thus reducing the risk of nosocomial transmission; and 3) saliva is relatively stable at a broad range of storage temperatures 35, 36 . Despite these advantages, there are also challenges facing COVID-19 saliva testing: 1) saliva has a broad range of virus loads (10-100,000 cp/µL) 37 ; 2) saliva contains many heterogeneous components, some of which are inhibitory to most diagnostic assays. As a result, RNA isolation is required for standard RT-qPCR methods for COVID-19 diagnosis with saliva samples.

The RT-LAMP assays we developed could directly detect the SARS-CoV-2 virus in saliva samples and were highly sensitive to cover a broad range of SARS-CoV-2 titers in patient saliva (10-100,000 cp/µL). Importantly, our RT-LAMP assays produced identical diagnostic results to RT-qPCR when directly applied to patient saliva samples. Interestingly, SARS-CoV-2 titers in these saliva samples varied greatly based on the RT-qPCR results. As for low virus titers, it is a challenge to sensitively detect the virus, whether using RT-LAMP or RT-qPCR. However, this is not likely a major issue for curbing the spread of COVID-19; multiple studies showed that, when the virus titer was below a certain level (<100-1,000 cp/µL in biofluid or Ct value >34), the patients are not likely to be spread disease [38] [39] [40] [41] .

Our RT-LAMP assays were fast as most reactions were completed within 30-45 min. Moreover, the assays could be easily adapted for point-of-care diagnosis with colorimetric readout under constant reaction temperature, or as a high-throughput screening assay in 384-well plate format.

In term of recently emerged SARS-CoV-2 variants, most identified mutations are located in the S gene sequence 42, 43 , and thus our validated assays focusing on the N and M genes will not likely be compromised by these mutations. In summary, we developed an improved algorithm All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. for LAMP assay design, and further validated the assays targeting SARS-COV-2. The design algorithm as well as the validated RT-LAMP assays provide powerful diagnostic tools to curb the pandemic of COVID-19. The LAMP or RT-LAMP assay in 10 µL reaction volume was used for primer screening and initial saliva assay optimization. A 20 µL reaction volume with the same reagent concentrations was subsequently adopted for assay validation using simulated and clinical saliva samples. For All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Total RNA was isolated using the mirVana kit (Life Technologies) according to recommended protocol.

Patient saliva samples were previously collected for COVID-19 diagnosis at a UIC clinical lab. In addition, we also analyzed pooled saliva samples from healthy individuals (Innovative Research). Saliva samples were first diluted with 0.9X volume of TE buffer (10 mM Tris, 1 mM EDTA pH 8.0). Then, 0.1X volume of 1X RNAsecure (25X, ThermoFisher) and 16 units/mL protease K (800 units/ml, NEB) were added to make 1:1 dilution of the saliva sample. The reaction mixture was incubated at 37°C for 10 min, 65°C for 10 min, and finally 95°C for 12 min to inactivate protease K. For spike-in experiments, heat-inactivated SAR-CoV-2 virus particles were added to the saliva before TE dilution. For patient saliva samples (n=20), they were first heated at 65°C for 30 min to inactivate the SARS-CoV-2 virus, and then further processed as described above. Four replicated reactions were performed directly for each saliva sample using two independent RT-LAMP assays. In addition, for each saliva sample, an aliquot (300 µL) was used for RNA isolation with the MagMAX Viral/Pathogen Nucleic Acid Isolation Kit (A42352, Applied Biosystems), followed by RT-qPCR or RT-LAMP analysis.

DNA sequencing libraries were prepared by PCR amplification of LAMP or RT-LAMP products with modified universal primers for Illumina sequencing. The indexed primers contain the P5 or P7 sequence for Illumina sequencing at the 5'-end, a 9-bp index sequence in the middle, followed by an adaptor sequence and a 3'-end F2 or B2 sequence specific to the LAMP assay.

The PCR reaction was set up by mixing 1 µL of diluted LAMP product, 1 µL of primer mix (10 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2021. ; https://doi.org/10.1101/2021.04.25.21256085 doi: medRxiv preprint µM), 12.5 µL of 2X PCR master mix (Tag Plus Master Mix Red, Lamda Biotech), and 10.5 µL of water. The PCR was performed at 94°C for 10 s, followed by 35 cycles of amplification (94°C for 10 s and 60°C for 45 s), and then 72°C for 1 min. The PCR products were purified with Ampure beads (Agencourt) and then quantified with QuantiFluor (Promega). The library samples were sequenced on MiniSeq (Illumina). The sequencing reads were aligned to the SARS-CoV-2 genome to identify virus-specific sequences. In addition, BLAST was performed to identify any sequence match to the NCBI GenBank database.

Supplemental data are available at the journal's website. The sequencing data are available at NCBI GEO under accession GSE173086.

National Institutes of Health (R01DE026471 and R01GM089784 to X.W., R56HL149881 to X.H. and 3R01ES028615-06S1 to N.I.). and X.W. interpreted the data and wrote the paper.

None declared.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Fig. 2D were analyzed on DNA agarose gel. On-target products showed typical DNA ladders (lanes 1-6) while non-specific products with high FP scores showed DNA smears (lanes 7-9).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The plasmid containing the N gene of SARS-CoV-2 (2,000 cp/reaction) was used as template for the LAMP reactions. The same color scheme as descried in Fig. 2B was used to represent the FP score. The arrows indicated selected LAMP assays with best overall performance in efficacy and specificity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2021. ; 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2021. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Step 3: Select compatible primer pairs

Step 4: Design F and B primer subsets

Cross-reactivity among all primers in the subset Cross-reactivity of paired primers

Step 5: Design LAMP primer sets

Step 2: Select single primers Exclude variable positions by aligning >100,000 genomes Cross-reactivity among all primers in the assay Primer length

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The coronavirus is here to stay -here's what that means

COVID-19 Infection Diagnosis: Potential Impact of Isothermal Amplification Technology to Reduce Community Transmission of SARS-CoV-2

Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection

Loop-mediated isothermal amplification of DNA

Sensitive and inexpensive molecular test for falciparum malaria: detecting Plasmodium falciparum DNA directly from heat-treated blood by loop-mediated isothermal amplification

Detection of Salmonella enterica in naturally contaminated liquid eggs by loop-mediated isothermal amplification, and characterization of Salmonella isolates

Rapid detection and typing of influenza A and B by loop-mediated isothermal amplification: comparison with immunochromatography and virus isolation

Development and validation of four one-step real-time RT-LAMP assays for specific detection of each dengue virus serotype

Development of a single-tube one-step RT-LAMP assay to detect the Chikungunya virus genome

Simultaneous diagnosis of dengue virus, Chikungunya virus, and Zika virus infection using a new point-of-care testing (POCT) system based on the loop-mediated isothermal amplification (LAMP) method

A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples

Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay

RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2

Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR

Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19

Specific detection of reverse transcription-loop-mediated isothermal amplification amplicons for Taura syndrome virus by colorimetric dot-blot hybridization

Real-time target-specific detection of loop-mediated isothermal amplification for white spot syndrome virus using fluorescence energy transfer-based probes

Efficient identification of clinically relevant 18

Loop-mediated isothermal amplification for detection of African trypanosomes

Primer design for RT-PCR

Accelerated reaction by loop-mediated isothermal amplification using loop primers

A PCR primer bank for quantitative gene expression analysis

A PCR-based platform for microRNA expression profiling studies

A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis

A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics

Thermodynamic parameters to predict stability of RNA/DNA hybrid duplexes

SIMPLE34: an improved and enhanced implementation for VAX and Sun computers of the SIMPLE algorithm for analysis of clustered repetitive motifs in nucleotide sequences

Priming efficiency in PCR

Mfold web server for nucleic acid folding and hybridization prediction. Nucleic 30

Rapid and Extraction-Free Detection of SARS-CoV-2 from Saliva by Colorimetric Reverse-Transcription Loop-Mediated Isothermal Amplification

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets

Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays

Point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP

Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices

Detection of SARS-CoV-2 in saliva: implications for specimen transport and storage

Viral dynamics of SARS-CoV-2 in saliva from infected patients

Virological assessment of hospitalized patients with COVID-2019

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

Longitudinal Surveillance for SARS-CoV-2 RNA Among Asymptomatic Staff in Five Colorado Skilled Nursing Facilities: Epidemiologic, Virologic and Sequence Analysis. medRxiv